Forskolin and Retinoic Acid Composition for Cisplatin Ototoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sensorineural hearing loss caused by ototoxic drugs, such as cisplatin anticancer drugs, are inadequate, with no clear molecular mechanism or effective method for prevention or treatment, and existing antioxidants only partially reduce ototoxicity without fully addressing the issue.
Innovation Solution
A pharmaceutical composition comprising forskolin and retinoic acid is developed to prevent or treat sensorineural hearing loss, which works by inhibiting apoptosis of auditory cells and preserving hair cells, supporting cells, and spiral ganglion cells, while maintaining the anticancer effect of cisplatin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antioxidants such as bucillamine, vitamin E, caffeic acid, and N-acetylcysteine are used to prevent cisplatin-induced hearing loss, then ototoxicity is reduced by increasing glutathione and reducing reactive oxide species, but potent preventive drugs have not been developed yet and hearing loss remains significant
Solution Approach 1:
The patent combines forskolin and retinoic acid into a single pharmaceutical composition to achieve synergistic protection against cisplatin-induced hearing loss. This combination approach merges the cAMP-activating properties of forskolin with the differentiation and survival properties of retinoic acid, creating a more potent preventive effect than either compound alone could achieve.
Solution Approach 2:
The invention uses a composite pharmaceutical formulation containing both forskolin and retinoic acid along with their respective carriers and excipients. This composite material approach allows the two active ingredients to work together in a coordinated manner, providing comprehensive protection against ototoxicity while maintaining acceptable drug delivery properties.
2Productivity
If cisplatin anticancer drugs are used to treat cancer, then excellent anticancer treatment effect is achieved, but hearing function is decreased in about 30% of users and in 50% of children
Solution Approach 1:
The patent introduces forskolin and retinoic acid as intermediary protective agents that are administered alongside cisplatin. These intermediaries do not interfere with the anticancer effect but rather mediate the protective effect against hearing loss by activating multiple cellular protection pathways including cAMP signaling, antioxidant production, and cell survival mechanisms.
3Object-affected harmful factors
If forskolin alone is used to protect against cisplatin-induced hearing loss, then cAMP activity is induced and oxidative damage is reduced, but hearing loss is not fully prevented
Solution Approach 1:
The patent merges forskolin with retinoic acid to create a synergistic protective effect. While forskolin alone provides cAMP-mediated antioxidant protection, the addition of retinoic acid enhances this effect by promoting hair cell differentiation and survival, thereby achieving more reliable hearing protection.
4Reliability
If retinoic acid alone is used to protect against hearing loss, then inner ear cell survival and differentiation are improved, but hearing loss is not fully prevented
Solution Approach 1:
The patent combines retinoic acid with forskolin to enhance the protective effect. While retinoic acid alone provides cell survival and differentiation benefits, the addition of forskolin adds cAMP-mediated antioxidant protection and reduces oxidative damage, thereby achieving more comprehensive hearing protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of forskolin and retinoic acid effectively ameliorates hearing loss by reducing oxidative damage and apoptosis, preserving auditory cells, and does not interfere with the anticancer effect of cisplatin, providing a more potent preventive and therapeutic approach than either compound alone.
Implementation Method 1
forskolin is a low-molecular-weight compound that activates adenylate cyclase and increases cAMP in cells
Implementation Method 2
retinoic acid is an essential component which is involved in the growth and differentiation of epithelial tissues through the regulation of expression of various genes
Implementation Method 3
cisplatin-induced oxidative damage in kidney cells is reduced through a pathway for inhibiting the synthesis of reactive oxygen species (ROS)
Data Source
AI summary
A pharmaceutical composition containing forskolin and retinoic acid as active ingredients which is suitable for preventing or treating sensorineural hearing loss is disclosed. A pharmaceutical composition containing forskolin and retinoic acid as active ingredients has an excellent effect of preventing, alleviating or treating hearing loss caused by ototoxic drugs during anticancer treatment, and thus is useful as a pharmaceutical composite preparation capable of reducing side effects of anticancer drugs and, additionally, as an agent for preventing or treating sensorineural hearing loss.